share_log

Merit Medical Systems' (NASDAQ:MMSI) Five-year Earnings Growth Trails the 27% YoY Shareholder Returns

Merit Medical Systems' (NASDAQ:MMSI) Five-year Earnings Growth Trails the 27% YoY Shareholder Returns

merit medical systems(NASDAQ:MMSI)五年收益增長低於股東回報的27% YoY
Simply Wall St ·  09/22 10:14

When you buy a stock there is always a possibility that it could drop 100%. But on the bright side, you can make far more than 100% on a really good stock. Long term Merit Medical Systems, Inc. (NASDAQ:MMSI) shareholders would be well aware of this, since the stock is up 227% in five years. It's also good to see the share price up 19% over the last quarter.

當您購買股票時,總有可能會下跌100%。但好的一面是,您可以在真正好的股票上獲得遠遠超過100%的回報。長期的Merit Medical Systems, Inc. (NASDAQ:MMSI)股東對此應該有所了解,因爲這隻股票在五年內上漲了227%。 這一季度,股價上漲了19%,也是一件好事。

Since it's been a strong week for Merit Medical Systems shareholders, let's have a look at trend of the longer term fundamentals.

由於Merit Medical Systems股東在本週表現強勁,讓我們來看看其長期基本面的趨勢。

In his essay The Superinvestors of Graham-and-Doddsville Warren Buffett described how share prices do not always rationally reflect the value of a business. By comparing earnings per share (EPS) and share price changes over time, we can get a feel for how investor attitudes to a company have morphed over time.

禾倫·巴菲特在他的論文《格雷厄姆-道德斯維爾的超級投資者》中描述了股票價格並不總是合理地反映企業的價值。通過比較每股收益(EPS)和股價隨時間變化的變化,我們可以了解到投資者對某家公司的態度如何隨時間而變化。

Over half a decade, Merit Medical Systems managed to grow its earnings per share at 23% a year. This EPS growth is reasonably close to the 27% average annual increase in the share price. Therefore one could conclude that sentiment towards the shares hasn't morphed very much. Rather, the share price has approximately tracked EPS growth.

在過去的五年中,Merit Medical Systems的每股收益年均增長23%。 這種每股收益的增長與該股票價格的年均增長27%相當接近。 因此,可以得出這樣的結論,即對該股票的情緒變化不大。 相反,股票價格幾乎與每股收益的增長相對應。

You can see how EPS has changed over time in the image below (click on the chart to see the exact values).

您可以在下面的圖片中查看每股收益如何隨時間變化(單擊圖表以查看確切的價值)。

big
NasdaqGS:MMSI Earnings Per Share Growth September 22nd 2024
2024年9月22日納斯達克成長技術指數:MMSI每股收益增長

It is of course excellent to see how Merit Medical Systems has grown profits over the years, but the future is more important for shareholders. This free interactive report on Merit Medical Systems' balance sheet strength is a great place to start, if you want to investigate the stock further.

看到美國醫療系統多年來利潤增長是很好的,但對股東來說,未來更重要。如果您想進一步研究該股票,Merit Medical Systems的資產負債表強度免費互動報告是一個很好的起點。

A Different Perspective

不同的觀點

It's good to see that Merit Medical Systems has rewarded shareholders with a total shareholder return of 46% in the last twelve months. That gain is better than the annual TSR over five years, which is 27%. Therefore it seems like sentiment around the company has been positive lately. Given the share price momentum remains strong, it might be worth taking a closer look at the stock, lest you miss an opportunity. If you would like to research Merit Medical Systems in more detail then you might want to take a look at whether insiders have been buying or selling shares in the company.

很高興看到美國醫療系統在過去十二個月裏回報股東總回報率爲46%。這一增長優於過去五年的年度TSR,爲27%。因此,最近的公司情緒似乎是積極的。鑑於股價動能仍然強勁,您可以更仔細地觀察該股票,以免錯過機會。如果您想對美國醫療系統進行更詳細的研究,您可能想查看公司內部人員是否一直在購買或出售股票。

If you are like me, then you will not want to miss this free list of undervalued small caps that insiders are buying.

如果您像我一樣,就不會希望錯過這份免費的內部人士正在購買的低估小市值股票列表。

Please note, the market returns quoted in this article reflect the market weighted average returns of stocks that currently trade on American exchanges.

請注意,本文所引述的市場回報反映了目前在美國交易所上市的股票的市場加權平均回報。

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

對本文有任何反饋?對內容有任何疑慮?請直接與我們聯繫。或者,發送電子郵件至editorial-team@simplywallst.com。
這篇文章是Simply Wall St的一般性文章。我們根據歷史數據和分析師預測提供評論,只使用公正的方法論,我們的文章並不意味着提供任何金融建議。文章不構成買賣任何股票的建議,也不考慮您的目標或您的財務狀況。我們的目標是帶給您基本數據驅動的長期關注分析。請注意,我們的分析可能不考慮最新的價格敏感公司公告或定性材料。Simply Wall St沒有任何股票頭寸。

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論